OKYO Pharma Completes Enrollment in Phase 2 Clinical Trial of OK-101 to treat Dry Eye Disease Full enrollment achieved on September 6 th with a total of 240 patients enrolled in study Top-line data planned for release in

Pharma Completes Enrollment in Phase 2 Clinical Trial of OK-101 to treat Dry Eye Disease

and New York, NY, September 8, 2023 - OKYO Pharma Limited (NASDAQ: OKYO), a clinical stage biopharmaceutical company developing

innovative therapies for the treatment of inflammatory dry eye disease ("DED), a multi-billion-dollar market, and for neuropathic

corneal pain ("NCP"), a severe ocular condition with no FDA approved therapy, is pleased to announce that it has completed

full enrollment of patients in the randomized portion of the Phase 2 multi-center, double-masked, placebo-controlled clinical trial of

topical ocular OK-101 to treat DED. A total of 240 patients have been enrolled in the study.

trial began in May of this year, and we have been pleased with the rapid pace of enrollment in the trial which has been managed by our

clinical development partner Ora Inc., a world leader in dry eye clinical research," said Gary S. Jacob, Ph.D., CEO of OKYO Pharma.

"We now have 240 patients enrolled in the trial and are anticipating the last-patient last-visit to occur in the last week of November

2023, with the planned release of top-line data occurring in December 2023."

Phase 2 clinical trial is a crucial step in the development of OK-101, evaluating its safety, efficacy, and tolerability in the population

of 240 DED patients comprising the study," said Raj Patil, Ph.D., CSO of OKYO Pharma. "We remain committed to establishing

the potential of this drug to treat the many millions of people currently suffering from DED."

is a common condition that occurs when one's tears are unable to adequately lubricate the eyes. This condition affects approximately

49 million people in the United States alone and has been difficult to positively diagnose and treat due to the multifactorial nature

of the condition. Several contributing factors can lead to this condition, including age, sex, certain medical conditions, reduced tear

production and tear film dysfunction. Tear film instability typically leads to inflammation and damage to the ocular surface and pain.

the Phase 2 Trial Design

phase 2, multi-center, randomized, double-blinded, placebo-controlled study is designed to enroll approximately 240 subjects with

DED who are being randomly divided into 3 cohorts of 80 patients. Participants are being selected based on specific inclusion and exclusion

criteria. The three cohorts include one cohort treated with placebo, a second cohort treated with 0.05% OK-101, and the third cohort

receiving 0.1% OK-101. The drug and placebo, respectively, are being administered in both eyes twice daily for 12 weeks. The duration

of a patient's treatment is approximately 14 weeks, including a 2-week run-in period, to address the placebo effect, which is common

for trials involving a pain component, followed by 12 weeks of treatment. The protocol for the study includes two prespecified primary

endpoints and a number of secondary endpoints. Further details regarding the specifics of the trial are posted on the clinicaltrials.gov

public website (clinicaltrials.gov Identifier: NCT05759208 or https://clinicaltrials.gov/ct2/results?term=Okyo&cond=Dry+Eye+Syndromes).

is a lipid conjugated chemerin peptide agonist of the ChemR23 G-protein coupled receptor which is typically found on immune cells of

the eye responsible for the inflammatory response. OK-101 was developed using a membrane-anchored-peptide (MAP) technology to produce

a novel long-acting drug candidate for treating dry eye disease. OK-101 has been shown to produce anti-inflammatory and pain-reducing

activities in mouse models of dry eye disease and corneal neuropathic pain, respectively, and is designed to combat washout through the

inclusion of the lipid anchor' contained in the drug molecule to enhance the residence time of OK-101 within the ocular

environment. OK-101 is currently in a Phase 2, multi-center, double-masked, placebo-controlled trial to treat dry eye disease.

Pharma Limited (NASDAQ: OKYO) is a clinical stage biopharmaceutical company developing innovative therapies for the treatment of inflammatory

DED) and NCP, with ordinary shares listed for trading on the NASDAQ Capital Market. OKYO is focused on the discovery and development

of novel molecules to treat inflammatory DED and ocular pain. OKYO presently has a 240-patient phase 2 trial of OK-101 underway to treat

patients with DED, and also has plans underway for the opening of a 40-patient trial of OK-101 to treat NCP in patients with this debilitating

condition. For further information, please visit www.okyopharma.com.

is a world-leading full-service ophthalmic drug and device development firm with offices in the United States, United Kingdom, Australia

and Asia. For over 40 years, the company has helped clients earn more than 50 product approvals. Ora's pre-clinical and clinical

models, unique methodologies, and global regulatory strategies have been refined and proven across thousands of global projects. The

company brings together the world's most extensive and experienced team of ophthalmic experts, R&D professionals, and management

executives to maximize the value of new product initiatives. For more information, please visit www.oraclinical.com, like us on

statements made in this announcement are forward-looking statements, including with respect to the anticipated timing of completion of

enrolment of the Company's Phase 2 trial of topical ocular OK-101 to treat DED and the release of top-line data therefrom. These

forward-looking statements are not historical facts but rather are based on the Company's current expectations, estimates, and

projections about its industry, its beliefs, and assumptions. Words such as anticipates,' expects,' intends,'

plans,' believes,' seeks,' estimates,' and similar expressions are intended to identify

forward-looking statements. These statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties,

and other factors, some of which are beyond the Company's control, are difficult to predict, and could cause actual results to

differ materially from those expressed or forecasted in the forward-looking statements. The Company cautions security holders and prospective

security holders not to place undue reliance on these forward-looking statements, which reflect the view of the Company only as of the

date of this announcement. The forward-looking statements made in this announcement relate only to events as of the date on which the

statements are made. The Company will not undertake any obligation to release publicly any revisions or updates to these forward-looking

statements to reflect events, circumstances, or unanticipated events occurring after the date of this announcement except as required

by law or by any appropriate regulatory authority.

further information, please visit the Company's website at www.okyopharma.com

person who arranged for the release of this announcement on behalf of the Company was Gary S. Jacob, Ph.D., Chief Executive Officer of